Improving 24-hour Blood Pressure in Obstructive Sleep Apnea
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study examines the combined effects of an angiotensin receptor blocker (ARB),
antioxidant supplementation, and continuous positive airway pressure (CPAP) therapy on the
lowering of 24-hour blood pressure in persons with moderate to severe Obstructive Sleep Apnea
(OSA). All participants will undergo CPAP therapy as prescribed by their doctor; however,
half of the participants will receive the combined ARB and antioxidant treatment while the
other half of the participants will receive a placebo.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of British Columbia
Collaborators:
Heart and Stroke Foundation of Canada Michael Smith Foundation for Health Research